Lena Thin

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 92 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 83 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +15

IgG4-related Sclerosing Disease of the Small Bowel Presenting as Necrotizing Mesenteric Arteritis and a Solitary Jejunal Ulcer

Daniel Wong, Sooraj Pillai, M. Priyanthi Kumarasinghe et al. · The American Journal of Surgical Pathology · 2012 · 40 citations

Medicine, Pathology, Autoimmunity +15

The Effect of Adiposity on Anti–Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients

Zixiang Lim, C. Welman, Warren Raymond et al. · Clinical and Translational Gastroenterology · 2020 · 35 citations · Full text

Medicine, Internal Medicine, Immunopathology +15